PPII Coenzyme A Inc (CE)

Pro-Pointer, Inc. (PINKSHEETS: PPII) through its wholly owned subsidiary Coenzyme A Technologies, Inc. is very pleased to announce its latest proprietary development the HEALTHY JOINT IMAGE T.M. "MODULATOR MATRIX IV" -- a revolutionary nutraceutical formula that especially addresses the symptoms of Arthritis and the painful and inflammatory conditions associated with stress and sports injuries to joints and connective tissues.

Arthritis sufferers include men and women, children and adults. Nearly 40-million persons are currently afflicted by Arthritis in the U.S. alone, including over a quarter of a million children. This represents an annual Twenty Billion Dollar Industry on Prescription drugs including the Over the Counter (NSAIDs) that are taken daily by consumers suffering from pain and the different forms of inflammatory conditions. These drugs while effective carry the burden of heavy warnings and side effects. These side effects include damage to the Cardiovascular system, Gastrointestinal bleeding, and Toxicity to both the Liver and the Kidneys. Due to these facts consumers are constantly seeking natural alternatives in order to manage their specific pain and inflammatory conditions.

The world Nutraceutical market which is expected to top $15 Billion this year has enjoyed double-digit growth over the last few years and is expected to continue. Growth is believed to be driven by new product introduction and the promotion of health consciousness and consumer awareness amongst the U.S. population.

"The HEALTHY JOINT IMAGE T.M. represents a new Nutraceutical development like no other on the market today," stated Nickolaos D. Skouras, Ph.D., President of Coenzyme A Technologies, Inc. "Unlike other natural alternative supplements that mimic the effects of prescription drugs (Cox-2 Inhibitors) our proprietary formula while effective in naturally reducing pain and inflammation also helps to rebuild the stomach lining that by now has been extensively damaged by the use of the above popular commercial products."

Pro-Pointer, Inc. plans to penetrate this market and to satisfy the ever growing consumer demand by continuing to develop new and innovative nutraceutical products, promoting them within their existing distribution channels, and implementing magazine advertising and aggressive world-wide internet marketing campaigns.

Given the above statistics and the ever rising demand for products that are effective in naturally addressing and correcting the symptoms of Arthritis and inflammatory conditions the HEALTHY JOINT IMAGE development represents a market value well exceeding the five million dollar annual revenues.

ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.

FORWARD-LOOKING STATEMENTS The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: InvestSource, Inc. 7071 Warner Aver. Suite F416 Huntington Beach CA. 92647 Email Contact Company 425-438-8586 www.coenzymea.com